Incyte-Novartis lung cancer drug shows promising results in Phase 2 trial

Delaware Business Now

Sep 5, 2020

Incyte announced that data from the Novartis Phase 2 GEOMETRY mono-1 study demonstrating that treatment with Tabrecta resulted in positive overall response rates for some patients…